ENTA will likely seek to develop a combination regimen of oral DAAs for SARS-CoV-2, but they haven’t committed to that, as far as I know. (ENTA has committed to developing an all-oral combination regimen for HBV.)
ENTA—Addendum to #msg-165295713: Your question came up on today’s CC. Jay Luly re-iterated that ENTA is looking at other (non-protease) MoAs against SARS-CoV-2, but he would not disclose which ones. He thinks monotherapy may be sufficient for acute treatment.
Market Data 
Markets 
AI
